Blog

SeerPharma Blog listing page

SeerPharma

Recent Posts

Data Security Support for Small Biotech Company

August 02, 2016

Cynata Therapeutics Limited is an Australian  stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™.

Read More

Good Aseptic Practices Training for Medical Device Company

July 27, 2016

Vaxxas is a Brisbane based Medical Device Company pioneering a next-generation vaccine delivery platform that enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the surface of the skin.

Read More

GMP Training in Malaysia

July 20, 2016

Malaysian Organisation of Pharmaceutical Industries (MOPI) was incorporated in 1981. The members consists of all manufacturers of pharmaceutical products whose manufacturing facilities are located in Malaysia and are licensed by the Drug Control Authority, Ministry of Health, Malaysia.

Read More

GMP Validation for Active Pharmaceutical Ingredient (API) Manufacturer

July 12, 2016

SeerPharma was asked to provide validation management and execution support for an established Active Pharmaceutical Ingredient (API) production facility in Australia.

Read More

Natural Health Brand Implements Online GMP Training Courses in Own LMS

July 04, 2016

After reviewing the market with a project to replace their existing GMP induction and refresher training program, a leading Australian natural health care brand has recognised the value of SeerPharma’s online GMP training solution.

Read More

Good Distribution Practice (GDP) Training in Asia

June 28, 2016

 Zuellig Pharma is Asia’s leading healthcare service provider offering a broad range of innovative services including distribution of pharmaceuticals, medical devices, special solutions and other healthcare related consumer products.

Read More

Effective Corrective and Preventive Action (CAPA) in a GMP Environment

June 23, 2016

 As a Pharmaceutical company, you are required to investigate the cause of quality failures or production problems. Surprisingly though, “Failure to thoroughly investigate…” is a common finding from regulatory inspections in the PIC/S, TGA and FDA GMP environment.

Read More

Medical Device Company Engages SeerPharma for ISO 13485 QMS

June 15, 2016

 SeerPharma has assisted an Australian 3D Printing Medical Device company to develop an ISO 13485 compliant Quality Management System (QMS).

Read More

Effective Corrective and Preventive Action (CAPA) for Medical Devices

June 09, 2016

As a Medical Device company, you are required to investigate the cause of quality failures or production problems. Surprisingly though, “Failure to thoroughly investigate…” is a common finding from quality (management) system inspections and audits against FDA 21 CFR Part 820 and ISO 13485.

Read More

FDA and TGA GMP Inspection Help for Pharmaceutical Company

June 07, 2016

An Australian pharmaceutical company engaged SeerPharma to prepare them for a TGA and FDA GMP inspection. Their Engineers were relatively inexperienced in dealing with regulatory inspections and the company required them to gain experience quickly in preparation for the FDA’s arrival. SeerPharma were requested to perform a mock audit to help meet...

Read More